Kezar Life Sciences, Inc. (KZR)
May 11, 2026 - KZR was delisted (reason: acquired by AUPH)
7.29
0.00 (0.00%)
Inactive · Last trade price on May 8, 2026
Kezar Life Sciences Earnings Call Transcripts
Fiscal Year 2025
-
Zidomipzomib showed strong efficacy and safety in refractory AIH, enabling significant steroid reduction and remission. Regulatory progress hinges on FDA review of an integrated safety summary, with pivotal trial planning underway and a large market opportunity identified.
Fiscal Year 2024
-
PORTOLA phase 2a data show zetomipzomib achieved significant biochemical remission and steroid tapering in refractory AIH, with durable responses and a favorable safety profile. The results support advancing to registrational trials, addressing a major unmet need in AIH.